[
  {
    "ticker": "IFT",
    "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02968812",
    "id": "02968812",
    "pages": 2,
    "price_sensitive": false,
    "date": "20250714",
    "time": "0750",
    "pdf_url": "https://announcements.asx.com.au/asxpdf/20250714/pdf/06lrlpl4zvvyw0.pdf",
    "summary": "<ul>\n<li><strong>Director Trading Disclosure</strong>: Jason Boyes (Director &amp; CEO of Infratil Limited) acquired <strong>45,393 IFT ordinary shares</strong> on-market between <strong>7-Jul-25 and 11-Jul-25</strong> at prices ranging from <strong>NZ$10.92251 to NZ$10.9584 per share</strong>.  </li>\n<li><strong>Total consideration</strong>: <strong>~NZ$497,329.75</strong>.  </li>\n<li><strong>Post-transaction holdings</strong>: <strong>2,427,830 shares</strong> (beneficially owned).  </li>\n</ul>\n<p><em>No material impact on capital structure or liquidity identified.</em></p>",
    "usage": {
      "prompt_tokens": 947,
      "completion_tokens": 118,
      "total_tokens": 1065,
      "prompt_tokens_details": null
    },
    "model": "deepseek/deepseek-chat-v3-0324:free",
    "processed_at": "2025-07-13T22:09:46.891849"
  },
  {
    "ticker": "PEB",
    "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02968811",
    "id": "02968811",
    "pages": 10,
    "price_sensitive": true,
    "date": "20250714",
    "time": "0730",
    "pdf_url": "https://announcements.asx.com.au/asxpdf/20250714/pdf/06lrlhgrd1s0s7.pdf",
    "summary": "<h3><strong>Capital Raising Announcement</strong></h3>\n<ul>\n<li><strong>Structure</strong>: Placement + Share Purchase Plan (SPP)  </li>\n<li><strong>Placement</strong>: AUD $16.1 million raised (oversubscribed) at $0.10/share (18% premium to 20-day VWAP).  </li>\n<li><strong>SPP</strong>: AUD $5 million targeted (potential oversubscription); retail shareholders eligible.  </li>\n<li><strong>Key Dates</strong>:  </li>\n<li><strong>Annual Meeting</strong>: 6 August 2025 (shareholder approval for placement required).  </li>\n<li><strong>SPP Opening</strong>: Mid-July 2025 (conditional on placement approval).  </li>\n</ul>\n<h3><strong>Operational Highlights (Q1 FY26)</strong></h3>\n<ul>\n<li><strong>US Test Volumes</strong>:  </li>\n<li>Total Laboratory Throughput (TLT): <strong>6,900 tests</strong> (down 8.9% QoQ).  </li>\n<li>US TLT: <strong>5,717 tests</strong> (down 11.9% QoQ) due to transition from <em>Detect</em> to <em>Triage</em>.  </li>\n<li><em>Triage</em> adoption: <strong>77% of US tests</strong> in June 2025 (vs. 22% in Q4 FY25).  </li>\n<li><strong>Asia Pacific Growth</strong>: <strong>1,183 tests</strong> (up 8.8% QoQ).  </li>\n<li><strong>Medicare Reconsideration</strong>: Positive discussions with Novitas; reconsideration request submitted for <em>Triage</em> (based on AUA Guideline inclusion and STRATA study).  </li>\n</ul>\n<h3><strong>Material Developments</strong></h3>\n<ol>\n<li><strong>Triage Plus Progress</strong>:  </li>\n<li>Analytical Validation published (Diagnostics, July 2025); supports Medicare reconsideration.  </li>\n<li>Draft Medicare price: <strong>US$1,018/test</strong> (vs. $760 for <em>Triage</em>). Pending DRIVE study peer review (submitted June 2025).  </li>\n<li><strong>AUA Guideline Impact</strong>:  </li>\n<li><em>Triage</em> holds \"Grade A\" evidence rating; drives payer negotiations (e.g., Optum VACCN coverage at Medicare rate).  </li>\n<li><strong>Cash Runway</strong>: Capital raise extends runway <strong>&gt;12 months</strong> without Medicare coverage.  </li>\n</ol>\n<hr />\n<p><strong>Omitted</strong>: Routine details on director re-elections, clinical study timelines (non-near-term), and regional breakdowns.<br />\n<strong>Key Focus</strong>: Capital structure, volume trends, Medicare strategy, and <em>Triage Plus</em> commercialization.</p>",
    "usage": {
      "prompt_tokens": 7214,
      "completion_tokens": 495,
      "total_tokens": 7709,
      "prompt_tokens_details": null
    },
    "model": "deepseek/deepseek-chat-v3-0324:free",
    "processed_at": "2025-07-13T22:10:10.943634"
  },
  {
    "ticker": "SNZ",
    "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02968810",
    "id": "02968810",
    "pages": 6,
    "price_sensitive": false,
    "date": "20250714",
    "time": "0730",
    "pdf_url": "https://announcements.asx.com.au/asxpdf/20250714/pdf/06lrlf7nq5f4mq.pdf",
    "summary": "<ul>\n<li><strong>Announcement Type:</strong> Employee incentive scheme securities issuance  </li>\n<li><strong>Securities Issued:</strong> 192,360 ordinary fully paid shares (ASX: SNZ)  </li>\n<li><strong>Issue Price:</strong> NZD 11.8757 per share  </li>\n<li><strong>Issue Date:</strong> 14/07/2025  </li>\n<li><strong>Ranking:</strong> Equally with existing shares  </li>\n<li><strong>Post-Issue Issued Capital:</strong> 241,123,378 ordinary shares on issue  </li>\n<li><strong>Key Management Personnel (KMP) Allocations:</strong>  </li>\n<li>Scott Scoullar: 84 shares  </li>\n<li>Margaret Warrington: 84 shares  </li>\n</ul>\n<p><em>No material impact on capital structure or liquidity expected (minor issuance under incentive scheme).</em></p>",
    "usage": {
      "prompt_tokens": 1489,
      "completion_tokens": 150,
      "total_tokens": 1639,
      "prompt_tokens_details": null
    },
    "model": "deepseek/deepseek-chat-v3-0324:free",
    "processed_at": "2025-07-13T22:09:52.172406"
  }
]